Nektar Therapeutics - stock earnings
NKTR Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 9, 2024 AfterMarket | - / -0.2100000000 | - | - / 15.3 million | - |
NKTR Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -42.1 million USD | 23.9 million USD |
| 2023Q3 | -45.8 million USD | 24.1 million USD |
| 2023Q2 | -51.1 million USD | 20.5 million USD |
| 2023Q1 | -137.0 million USD | 21.6 million USD |
| 2022Q4 | -59.7 million USD | 22.0 million USD |
| 2022Q3 | -59.0 million USD | 23.6 million USD |
| 2022Q2 | -159.1 million USD | 21.6 million USD |
| 2022Q1 | -90.4 million USD | 24.8 million USD |
| 2021Q4 | -145.6 million USD | 25.0 million USD |
| 2021Q3 | -129.7 million USD | 24.9 million USD |
| 2021Q2 | -125.5 million USD | 28.3 million USD |
| 2021Q1 | -123.0 million USD | 23.6 million USD |
| 2020Q4 | -117.2 million USD | 23.5 million USD |
| 2020Q3 | -108.6 million USD | 30.0 million USD |
| 2020Q2 | -80.0 million USD | 48.8 million USD |
| 2020Q1 | -138.7 million USD | 50.6 million USD |
| 2019Q4 | -112.2 million USD | 33.9 million USD |
| 2019Q3 | -98.8 million USD | 29.2 million USD |
| 2019Q2 | -109.9 million USD | 23.3 million USD |
| 2019Q1 | -118.5 million USD | 28.2 million USD |
| 2018Q4 | -98.2 million USD | 39.8 million USD |
| 2018Q3 | -96.1 million USD | 27.8 million USD |
| 2018Q2 | 971.5 million USD | 1.1 billion USD |
| 2018Q1 | -95.8 million USD | 38.0 million USD |
| 2017Q4 | -33.8 million USD | 95.5 million USD |
| 2017Q3 | 60.9 million USD | 152.9 million USD |
| 2017Q2 | -59.9 million USD | 34.6 million USD |
| 2017Q1 | -63.9 million USD | 24.7 million USD |
| 2016Q4 | -42.2 million USD | 37.5 million USD |
| 2016Q3 | -43.2 million USD | 36.3 million USD |
| 2016Q2 | -48.6 million USD | 32.8 million USD |
| 2016Q1 | -19.5 million USD | 58.9 million USD |
| 2015Q4 | -54.1 million USD | 39.4 million USD |
| 2015Q3 | -8.2 million USD | 60.0 million USD |
| 2015Q2 | -52.7 million USD | 22.7 million USD |
| 2015Q1 | 33.8 million USD | 108.8 million USD |
| 2014Q4 | -45.7 million USD | 19.6 million USD |
| 2014Q3 | 70.6 million USD | 132.9 million USD |
| 2014Q2 | -32.6 million USD | 28.5 million USD |
| 2014Q1 | -46.2 million USD | 19.8 million USD |
| 2013Q4 | -47.7 million USD | 31.1 million USD |
| 2013Q3 | -16.5 million USD | 60.9 million USD |
| 2013Q2 | -42.7 million USD | 33.9 million USD |
| 2013Q1 | -55.1 million USD | 23.0 million USD |
| 2012Q4 | -52.9 million USD | 21.1 million USD |
| 2012Q3 | -43.5 million USD | 18.4 million USD |
| 2012Q2 | -34.3 million USD | 23.7 million USD |
| 2012Q1 | -41.1 million USD | 17.9 million USD |
| 2011Q4 | -37.5 million USD | 15.8 million USD |
| 2011Q3 | -24.1 million USD | 27.1 million USD |
| 2011Q2 | -36.4 million USD | 17.3 million USD |
| 2011Q1 | -36.0 million USD | 11.3 million USD |
| 2010Q4 | -22.6 million USD | 45.3 million USD |
| 2010Q3 | -8.7 million USD | 37.9 million USD |
| 2010Q2 | -517000 USD | 42.6 million USD |
| 2010Q1 | -6.1 million USD | 33.2 million USD |
| 2009Q4 | -7.7 million USD | 39.0 million USD |
| 2009Q3 | -31.0 million USD | 10.2 million USD |
| 2009Q2 | -32.1 million USD | 13.0 million USD |
| 2009Q1 | -31.8 million USD | 9.7 million USD |
| 2008Q4 | 76.8 million USD | 28.4 million USD |
| 2008Q3 | -37.0 million USD | 21.4 million USD |
| 2008Q2 | -33.4 million USD | 20.4 million USD |
| 2008Q1 | -40.7 million USD | 20.0 million USD |
| 2007Q4 | 39.0 million USD | 65.8 million USD |
| 2007Q3 | -18.6 million USD | 56.3 million USD |
| 2007Q2 | -27.5 million USD | 65.9 million USD |
| 2007Q1 | -25.7 million USD | 85.0 million USD |
| 2006Q4 | -38.9 million USD | 69.9 million USD |
| 2006Q3 | -19.6 million USD | 58.6 million USD |
| 2006Q2 | -62.8 million USD | 60.2 million USD |
| 2006Q1 | -33.5 million USD | 29.0 million USD |
| 2005Q4 | -108.2 million USD | 32.9 million USD |
| 2005Q3 | -23.8 million USD | 36.4 million USD |
| 2005Q2 | -26.9 million USD | 28.6 million USD |
| 2005Q1 | -26.2 million USD | 28.5 million USD |
| 2004Q4 | -19.3 million USD | 31.4 million USD |
| 2004Q3 | -20.5 million USD | 28.5 million USD |
| 2004Q2 | -22.2 million USD | 28.5 million USD |
| 2004Q1 | -40.0 million USD | 25.8 million USD |
| 2003Q4 | 3.5 million USD | 25.6 million USD |
| 2003Q3 | -17.2 million USD | 27.4 million USD |
| 2003Q2 | -13.0 million USD | 27.7 million USD |
| 2003Q1 | -19.9 million USD | 25.5 million USD |
| 2002Q4 | -31.1 million USD | 22.6 million USD |
| 2002Q3 | -26.5 million USD | 23.2 million USD |
| 2002Q2 | -24.8 million USD | 22.3 million USD |
| 2002Q1 | -36.3 million USD | 24.2 million USD |
| 2001Q4 | -36.3 million USD | 24.2 million USD |
| 2001Q3 | -26.9 million USD | 22.4 million USD |
| 2001Q2 | -105.8 million USD | 16.8 million USD |
| 2001Q1 | -81.0 million USD | 14.1 million USD |
| 2000Q4 | -39.6 million USD | 13.1 million USD |
| 2000Q3 | -13.2 million USD | 14.1 million USD |
| 2000Q2 | -15.7 million USD | 13.8 million USD |
| 2000Q1 | -28.8 million USD | 10.6 million USD |
| 1999Q4 | -20.2 million USD | 13.1 million USD |
| 1999Q3 | -7.0 million USD | 10.6 million USD |
| 1999Q2 | -6.0 million USD | 9.9 million USD |
| 1999Q1 | -5.2 million USD | 7.8 million USD |
| 1998Q4 | -6.3 million USD | 6.4 million USD |
| 1998Q3 | -5.0 million USD | 4.9 million USD |
| 1998Q2 | -2.9 million USD | 6.7 million USD |
| 1998Q1 | -4.1 million USD | 3.9 million USD |
| 1997Q4 | -3.0 million USD | 4.8 million USD |
| 1997Q3 | -2.7 million USD | 4.3 million USD |
| 1997Q2 | -2.3 million USD | 4.0 million USD |
| 1997Q1 | -2.0 million USD | 3.2 million USD |
| 1996Q4 | -3.4 million USD | 2.2 million USD |
| 1996Q3 | -2.3 million USD | 1.8 million USD |
| 1996Q2 | -2.5 million USD | 1.4 million USD |
| 1996Q1 | -1.9 million USD | 1.5 million USD |
| 1995Q4 | -2.3 million USD | 800000 USD |
| 1995Q3 | -1.7 million USD | 1.0 million USD |
| 1995Q2 | -1.6 million USD | 1.0 million USD |
| 1995Q1 | -2.2 million USD | 600000 USD |
| 1994Q4 | -2.3 million USD | 500000 USD |
| 1994Q3 | -900000 USD | 600000 USD |
| 1994Q2 | -900000 USD | 300000 USD |
| 1994Q1 | -1.1 million USD | 400000 USD |
NKTR Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -276.1 million USD | 90.1 million USD |
| 2022 | -368.2 million USD | 92.1 million USD |
| 2021 | -523.8 million USD | 101.9 million USD |
| 2020 | -444.4 million USD | 152.9 million USD |
| 2019 | -440.7 million USD | 114.6 million USD |
| 2018 | 681.3 million USD | 1.2 billion USD |
| 2017 | -96.7 million USD | 307.7 million USD |
| 2016 | -153.5 million USD | 165.4 million USD |
| 2015 | -81.2 million USD | 230.8 million USD |
| 2014 | -53.9 million USD | 200.7 million USD |
| 2013 | -162.0 million USD | 148.9 million USD |
| 2012 | -171.9 million USD | 81.2 million USD |
| 2011 | -134.0 million USD | 71.5 million USD |
| 2010 | -37.9 million USD | 159.0 million USD |
| 2009 | -102.5 million USD | 71.9 million USD |
| 2008 | -34.3 million USD | 90.2 million USD |
| 2007 | -32.8 million USD | 273.0 million USD |
| 2006 | -154.8 million USD | 217.7 million USD |
| 2005 | -185.1 million USD | 126.3 million USD |
| 2004 | -101.9 million USD | 114.3 million USD |
| 2003 | -46.7 million USD | 106.3 million USD |
| 2002 | -107.5 million USD | 94.8 million USD |
| 2001 | -250.0 million USD | 77.5 million USD |
| 2000 | -97.4 million USD | 51.6 million USD |
| 1999 | -38.4 million USD | 41.4 million USD |
| 1998 | -18.4 million USD | 21.8 million USD |
| 1997 | -10.0 million USD | 16.2 million USD |
| 1996 | -10.0 million USD | 6.9 million USD |
| 1995 | -7.7 million USD | 3.4 million USD |
| 1994 | -5.3 million USD | 1.7 million USD |
NKTR
Price: $1.52
52 week price:
Earnings Per Share: -1.45 USD
P/E Ratio: -0.38
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.8 million
Ebitda: 74.9 millionMarket Capitalization: 242.4 million